A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker
Tyrosine kinase inhibitors (TKI) that block epidermal growth factor receptor (EGFR) pathway
have demonstrated a clinical benefit for patients with non-small-cell lung cancer (NSCLC) …
have demonstrated a clinical benefit for patients with non-small-cell lung cancer (NSCLC) …
Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer: A case report and literature …
F Wu, S Zhang, G Gao, J Zhao, S Ren… - Cancer Biology & …, 2018 - Taylor & Francis
Although targeted therapy directed toward driver mutations has produced a significant
efficacy benefit for patients with non-small cell lung cancer (NSCLC), many patients do not …
efficacy benefit for patients with non-small cell lung cancer (NSCLC), many patients do not …
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor …
S Lu, L Wu, H Jian, Y Cheng, Q Wang… - The Lancet …, 2023 - thelancet.com
Background In the first interim analysis of the ORIENT-31 trial, compared with chemotherapy
alone, sintilimab plus bevacizumab biosimilar IBI305 plus chemotherapy (pemetrexed and …
alone, sintilimab plus bevacizumab biosimilar IBI305 plus chemotherapy (pemetrexed and …
[HTML][HTML] Apatinib for heavily treated patients with non-small cell lung cancer: Report of a case series and literature review
D Yang, R Dai, Q Zhang, P Fang - Saudi Journal of Biological Sciences, 2018 - Elsevier
Although many strategies have been developed for non-small cell lung cancer (NSCLC),
more secondary and further treatments are needed due to drug resistance or tumor …
more secondary and further treatments are needed due to drug resistance or tumor …
P76. 03 Efficacy and safety of capmatinib plus nivolumab in pretreated patients with EGFR wild-type non–small cell lung cancer
Methods This phase 2 trial (NCT02323126) evaluated the efficacy and safety of capmatinib
plus nivolumab in patients with advanced/metastatic EGFR wild-type NSCLC who had …
plus nivolumab in patients with advanced/metastatic EGFR wild-type NSCLC who had …
[HTML][HTML] Afatinib in non–small cell lung cancer
SM Wirth - Journal of the Advanced Practitioner in Oncology, 2015 - ncbi.nlm.nih.gov
Lung cancer is the second most common cancer and the leading cause of cancer-related
deaths in both men and women (Siegel, Ma, Zou, & Jemal, 2014). Non–small cell lung …
deaths in both men and women (Siegel, Ma, Zou, & Jemal, 2014). Non–small cell lung …
Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study
TH Kim, JH Choi, MS Ahn, HW Lee, SY Kang, YW Choi… - BMC cancer, 2024 - Springer
Background Both first and second-generation EGFR-TKIs are recommended in advanced
NSCLC with common EGFR mutations. However, there are few data on the difference in …
NSCLC with common EGFR mutations. However, there are few data on the difference in …
Anlotinib plus Icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis …
L Zhang, L Wang, J Wang, J Chen, Z Meng, Z Liu… - Molecular Cancer, 2023 - Springer
Background Non-small cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …
Study of anlotinib combined with icotinib as the first-line treatment in non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations (ALTER-L004).
D Huang, D Zhong, C Zhang, Y Zhang, Y Shang… - 2020 - ascopubs.org
9573 Background: Anti-angiogenic monoclonal antibodies plus EGFR TKIs have previously
shown to prolong PFS in patients with EGFR-mutated NSCLC (JO25567 and NEJ026) …
shown to prolong PFS in patients with EGFR-mutated NSCLC (JO25567 and NEJ026) …
Efficacy and safety of apatinib as third-or further-line therapy for patients with advanced NSCLC: a retrospective study
J Liang, W Gu, J Jin, H Zhang, Z Chen… - Therapeutic …, 2020 - journals.sagepub.com
Background: Apatinib, an oral small-molecule angiogenesis inhibitor, selectively inhibits
vascular endothelial growth factor receptor 2 (VEGFR-2), which inhibits vascular endothelial …
vascular endothelial growth factor receptor 2 (VEGFR-2), which inhibits vascular endothelial …